XTX Technology recently submitted its listing application to the Hong Kong Stock Exchange. According to CIC, by 2024 revenue, the company ranked sixth among global code-type flash memory chip fabless companies with a 3.7% market share. The prospectus shows that the company's revenue was RMB 442 million with a net loss of RMB 37.136 million in 2024, but achieved a profit turnaround in the first nine months of 2025.
CES 2026 takeaway: memory-rich end-to-end agents will replace toolkits within 24 mos; charge early—AI inference cost kills freemium.
Unique Research's CES 2026 closed-door dialogue reveals AI companies must abandon internet-era thinking and adopt "tiered subscription + usage limits" hybrid models. Tanka CEO Kisson Lin and Emmy-nominated producer Jesse Z analyze market selection, localization, fundraising, and pricing strategies, declaring the freemium model dead. AI firms should charge early to validate value, with future AI evolving into autonomous Agents with enhanced memory and contextual capabilities.
Biocytogen (2315) announced on January 12 an option and license agreement with Acepodia, granting global exclusive options on two BsADC projects to accelerate bispecific antibody-dual drug conjugate (BsAD2C) development. Biocytogen will receive upfront and subsequent milestone payments plus royalties. The collaboration combines Biocytogen's RenLite® platform with Acepodia's AD2C technology, building upon a joint development partnership initiated earlier this year. Acepodia and its ultimate beneficial owners are independent of Biocytogen and its connected persons, and the transaction does not constitute a connected transaction. The company cautions shareholders and potential investors to exercise prudence when trading its shares.
Brain-computer interfaces became a market hotspot in early 2026, primarily driven by news that Neuralink—under Elon Musk—plans to mass-produce devices in 2026. According to public information, Neuralink has completed multiple human implantations, with its invasive technology path aimed at treating neurological diseases. Kaiyuan Securities analysis points out that the industry is still in the early stages of commercialization, with the market characterized by thematic investment style.
Peking University Resources (Holdings) Company Limited (00618.HK) announced that ResoHealth, the Group’s Dubai-based healthcare business unit, has partnered with Trivitron Healthcare to launch the Trivitron Digital AI Digital Health Initiative in India. The platform aims to enhance the operational efficiency of hospitals and the patient diagnosis and treatment experience in India’s tier-2 and tier-3 cities through cloud solutions and AI technologies, with future plans to expand into the African, Middle Eastern and Southeast Asian markets.
MIRXES-B (02629.HK) announced that it has established a strategic cooperation with N Health, an affiliate of BDMS (Bangkok Dusit Medical Services (BDMS) Group)—Thailand’s largest healthcare provider—to jointly promote miRNA cancer screening solutions in Thailand. In addition, two of the Company’s at-home test kits (Helicobacter pylori and fecal occult blood tests) have obtained approval from Thailand’s FDA and are officially launched on January 9, 2026.
Galaxis Technology has re-submitted its listing application to the Hong Kong Exchanges and Clearing Limited (HKEX) in recent days. According to data from Frost & Sullivan, based on shipment volume in 2024, the company is the largest supplier in China's Very Narrow Aisle Autonomous Mobile Robot (VNA AMR) sector, with a market share of 19.3%. The prospectus shows that the company recorded an operating revenue of RMB 721 million in 2024, yet it has not achieved profitability during the reporting period, with a significant cumulative loss.
Standard Robots filed a prospectus with the Hong Kong Stock Exchange again, with CITIC Securities and Guotai Junan International as joint sponsors. According to China Insights Consultancy, Standard Robots ranked among China's four major industrial intelligent mobile robot solution providers by sales volume in 2024. For the first nine months of 2025, revenue was RMB 188 million, up 19.7% year-over-year, while the loss for the period was RMB 163 million, representing an expansion compared to the same period last year.
New Shicoh Motor recently filed a listing application with the Hong Kong Stock Exchange, with CICC and Huatai International as joint sponsors. According to a Frost & Sullivan report, the company is China's largest optical image stabilization imaging motor supplier by 2024 revenue, holding a 20.1% market share. The prospectus shows the company achieved 2024 revenue of RMB 1.565 billion and swung to profitability with a net profit of RMB 105 million.
HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.
Beijing Saimo Technology (2571) announced that it will introduce investors to inject RMB12.0098 million into its subsidiary Zhejiang Saimo in exchange for 49% equity, reducing its stake to 51% while maintaining consolidation. The valuation is approximately RMB12.116 million using the asset-based approach. The transaction constitutes a discloseable transaction under Listing Rules, with the cash portion to be used for R&D and no gain or loss expected to be recognized.
Leadrive Technology recently filed a prospectus with the Hong Kong Stock Exchange for a Main Board listing, with CITIC Securities and Haitong International as joint sponsors. According to Frost & Sullivan, by installed capacity in the first three quarters of 2025, the company's motor controllers ranked eighth, dual-motor controllers ranked third; main drive power bricks ranked second, and power bricks for dual-motor controllers ranked first.
Beijing Roborock Technology has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 33,108,000 shares. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
UISEE Technology (Beijing) has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 18,914,150 shares and conversion of 112,264,250 domestic shares held by 41 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
Beijing Haizhi Technology Group has received CSRC filing approval for its proposed Hong Kong IPO of up to 47,584,600 shares and conversion of 372,400,480 domestic shares held by 40 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
